Exhaled nitric oxide in systemic sclerosis: Relationships with lung involvement and pulmonary hypertension

Journal of Rheumatology

Volumn 27, Issue 7, 2000, Pages 1693-1698

  Rolla, Giovanni ^a   Colagrande, Paola ^a   Scappaticci, Ermanno ^a   Chiavassa, Giovanni ^a   Dutto, Luca ^a   Cannizzo, Silvana ^a   Bucca, Caterina ^a   Morello, Mara ^a   Bergerone, Serena ^a   Bardini, Daniela ^a   Zaccagna, Alessandro ^a   Puiatti, Paolo ^a   Fava, Cesare ^a   Cortese, Giancarlo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Exhaled nitric oxide; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

NITRIC OXIDE;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS;

ADULT; AGED; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY ARTERY; RESPIRATORY FUNCTION TESTS; RESPIRATORY PHYSIOLOGY; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033910117     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
2. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
3. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978;64:998-1004.
4. Norton WL, Nardo JM. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970;73:317-24.
5. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997;24:81-5.
6. Kharitonov SA, Cailes JB, Black CM, duBois RM, Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997;52:1051-5.
7. Barnes PJ, Belvisi MG. Nitric oxide and lung disease. Thorax 1993;48:1034-43.
8. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5.
9. Stamler JS, Loh E, Roddy M, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035-40.
10. Ignarro LJ, Byrus RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide. Circ Res 1987;61:866-79.
11. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J 1992;5:757-62.
12. Fineman JR, Chang R, Soifer SJ. EDRF inhibition augments pulmonary hypertension in intact newborn lambs. Am J Physiol 1992;262:H1365-71.
13. Archer SL, Tolins JP, Raij L, Weir EK. Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. Biochem Biophys Res Commun 1989;164:1198-205.
14. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-47.
15. Giaid AG, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
16. Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1061-7.
17. Al-Ali MK, Howarth PH. Nitric oxide and the respiratory system in health and disease. Respir Med 1998;92:701-15.
18. Rolla G, Brussino L, Bertero MT, et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol 1997;24:1066-71.
19. Fajac I, Kahan A, Menkes CJ, Dessanges JF, Dall' Ava-Santucci J, Dinh-Xuan AT. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 1998;16:547-52.
20. Murrel DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
22. American Thoracic Society Executive Committee. Recommended standardized procedures for pulmonary testing. Am Rev Respir Dis 1978;118:55-72.
23. American Thoracic Society. Single breath carbon monoxide diffusing capacity (transfer factor): Recommendation for a standard technique - 1995 update. Am J Respir Crit Care Med 1995;152:2185-98.
24. Quanjer PH, editor. Standardized lung function testing. Bull Europ Physiopath Respir 1983; 5 Suppl 19:45-51.
25. Kharitonov SA, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 1997;10:1683-93.
26. Lundberg JO, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg JM, Alving K. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur Respir J 1994;7:1501-4.
27. Collins CD, Wells AU, Morgan RA, et al. Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography. Clin Radiol 1994;49:236-40.
28. Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in the exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J 1995;8:295-7.
29. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:998-1002.
30. Kharitonov SA, Wells A, O'Connor B, et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995;151:1889-93.
31. Bjerke RD, Tashkin DP, Clements PJ, Chopra SK, Gong H Jr, Bein M. Small airways in progressive systemic sclerosis. Am J Med 1979;66:201-9.
32. Paredi P, Kharitonov SA, Loukides S, Pantelidis P, DuBois RM, Barnes PJ. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999;115:1352-6.
33. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:1763-9.
34. Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992;47:508-12.
35. Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A. Importance of ground glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993;189:693-8.
36. Sumino H, Sato K, Sakamaki T, et al. Decreased basal production of nitric oxide in patients with heart disease. Chest 1998; 113:317-22.
37. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993;92:99-104.
38. DeGraaf JC, Banga JD, Moncada S, Palmer RM, DeGroot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-90.
39. Baudouin SV, Bath P, Martin JF, DuBois R, Evans TW. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 1993;36:45-9.
40. Mehta S, Stewart DJ, Levy RD. The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest 1996;109:1550-5.
41. Rolla G, Colagrande P, Brussino L, Bucca C, Bertero MT, Caligaris-Cappio F. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. Lancet 1998;351:1491-2.